Paxton J W
Clin Pharmacol Ther. 1980 Feb;27(2):170-8. doi: 10.1038/clpt.1980.26.
In vitro studies have shown that phenytoin (DPH) is displaced from plasma protein binding sites by some drugs. These results have been extrapolated to suggest that, in vivo, this may cause a rise in the free concentration, leading to a greater pharmacologic effect. We examined the effects of aspirin on the levels and kinetics of total serum DPH and free drug as represented by salivary concentrations in 7 healthy subjects. Aspirin induced a decrease (mean, 27.4 +/- 3.7%) in total serum DPH concentration but no corresponding change in salivary concentration. During continued aspirin administration, no change was observed in elimination half-life (t 1/2 beta) of total serum DPH but there was a trend toward reduced t 1/2 beta in saliva. The ratio of saliva to total serum DPH concentration also increased during this period. These results suggest that displacement of DPH from plasma protein binding sites does not result in an increase in free concentration and thus increased pharmacologic activity, but any previous relationship between total serum concentration and therapeutic effect will no longer hold, as a greater proportion of the total concentration will be in the free form and therapeutically active.
体外研究表明,苯妥英(DPH)会被某些药物从血浆蛋白结合位点上置换下来。这些结果被推断表明,在体内,这可能会导致游离浓度升高,从而产生更大的药理作用。我们研究了阿司匹林对7名健康受试者血清总DPH水平及动力学以及唾液浓度所代表的游离药物的影响。阿司匹林导致血清总DPH浓度降低(平均降低27.4±3.7%),但唾液浓度无相应变化。在持续给予阿司匹林期间,血清总DPH的消除半衰期(t 1/2β)未观察到变化,但唾液中的t 1/2β有降低趋势。在此期间,唾液与血清总DPH浓度的比值也增加。这些结果表明,DPH从血浆蛋白结合位点的置换不会导致游离浓度增加,从而不会增加药理活性,但血清总浓度与治疗效果之间以前的任何关系将不再成立,因为总浓度中更大比例将以游离形式存在并具有治疗活性。